Texas Statutes
Subchapter A. Prescription and Substitution Requirements
Section 562.0051. Communication Regarding Certain Dispensed Biological Products

Sec. 562.0051. COMMUNICATION REGARDING CERTAIN DISPENSED BIOLOGICAL PRODUCTS. (a) Not later than the third business day after the date of dispensing a biological product, the dispensing pharmacist or the pharmacist's designee shall communicate to the prescribing practitioner the specific product provided to the patient, including the name of the product and the manufacturer or national drug code number.
(b) The communication must be conveyed by making an entry into an interoperable electronic medical records system or through electronic prescribing technology or a pharmacy benefit management system or a pharmacy record, which may include information submitted for the payment of claims, that a pharmacist reasonably concludes is electronically accessible by the prescribing practitioner. Otherwise, the pharmacist or the pharmacist's designee shall communicate the biological product dispensed to the prescribing practitioner, using facsimile, telephone, electronic transmission, or other prevailing means, provided that communication is not required if:
(1) there is no interchangeable biological product approved by the United States Food and Drug Administration for the product prescribed; or
(2) a refill prescription is not changed from the product dispensed on the prior filling of the prescription.
(c) Repealed by Acts 2019, 86th Leg., R.S., Ch. 13 (H.B. 1264), Sec. 1, eff. May 7, 2019.
Added by Acts 2015, 84th Leg., R.S., Ch. 1007 (H.B. 751), Sec. 5, eff. September 1, 2015.
Amended by:
Acts 2019, 86th Leg., R.S., Ch. 13 (H.B. 1264), Sec. 1, eff. May 7, 2019.

Structure Texas Statutes

Texas Statutes

Occupations Code

Title 3 - Health Professions

Subtitle J - Pharmacy and Pharmacists

Chapter 562 - Practice by License Holder

Subchapter A. Prescription and Substitution Requirements

Section 562.001. Definitions

Section 562.002. Legislative Intent

Section 562.003. Disclosure of Price; Patient's Option

Section 562.004. Prescription Transmitted Orally by Practitioner

Section 562.005. Record of Dispensed Drug or Biological Product

Section 562.0051. Communication Regarding Certain Dispensed Biological Products

Section 562.006. Label

Section 562.0061. Other Prescription Information

Section 562.0062. Required Statement Regarding Medication Disposal

Section 562.007. Refills

Section 562.008. Generic Equivalent or Interchangeable Biological Product Authorized

Section 562.009. Requirements Concerning Selection of Generically Equivalent Drug or Interchangeable Biological Product

Section 562.010. Responsibility Concerning Generically Equivalent Drug or Interchangeable Biological Product; Liability

Section 562.011. Restriction on Selection of and Charging for Generically Equivalent Drug or Interchangeable Biological Product

Section 562.012. Substitution of Dosage Form Permitted

Section 562.013. Applicability of Subchapter

Section 562.014. Narrow Therapeutic Index Drugs

Section 562.0141. Transplant Immunosuppressant Drug Product Selection Prohibited

Section 562.0142. Adoption of Rules

Section 562.015. Dispensing Directive; Compliance With Federal Law

Section 562.016. List of Approved Interchangeable Biological Products